摘要
由于胃癌具有较高的肿瘤内及肿瘤间异质性,导致患者在免疫治疗疗效和预后方面差异极大。程序性死亡受体配体1、人表皮生长因子受体2、肿瘤微环境特征、外周血炎性标志物及Claudin18.2等多种生物标志物均显示出对免疫治疗疗效和患者预后的预测价值,有助于临床医生筛选免疫治疗潜在获益人群,实现精准化治疗。
The high intra-and inter-tumor heterogeneity of gastric cancer leads to a great difference in the immunotherapy efficacy and the prognosis among patients.Several biomarkers,including programmed death-ligand 1,human epidermal growth factor receptor 2,the features of tumor microenvironment,the peripheral blood inflammatory markers and Claudin18.2 have predictive value in the immunotherapy efficacy and the prognosis of gastric cancer patients,which might help the clinicians find the potential patients who will benefit from immunotherapy,and achieve the goal of precision medicine.
作者
刘玉兰
井海燕
孙静
宋伟
沙丹
Liu Yulan;Jing Haiyan;Sun Jing;Song Wei;Sha Dan(Second Clinical Medical College of Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Department of Minimally Invasive Comprehensive Treatment to Cancer,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Department of Pathology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)
出处
《国际肿瘤学杂志》
CAS
2024年第3期175-180,共6页
Journal of International Oncology
基金
山东省自然科学基金(ZR2021MH140)
济南市临床医学科技创新计划(202019085)。
关键词
胃肿瘤
免疫疗法
预测
生物标记
肿瘤
预后
Stomach neoplasms
Immunotherapy
Forecasting
Biomarkers
tumor
Prognosis
